Truist Securities analysts raised the price target on BioNTech SE (NASDAQ:BNTX) from $151 to $155 and kept a “Buy” rating.

Taiwan Semiconductor Manufacturing Company TSM has delivered a solid 12.6% gain over the past three months. This performance ...